Brain metastases are the most frequently occurring neurologic complications of cancer in adults, with 9 -17% of all cancers resulting in brain metastasis and brain metastasis 
brain metastases (such as proximity to sites of vital brain function), co-existing morbidities, and symptoms [2, 5] .
Glioblastoma multiforme (WHO Classification astrocytoma Grade IV), a metastatic primary brain tumour, accounts for 12 -15% of all brain tumours [6] and is the most common primary brain tumour in adults [7] . Glioblastoma is an aggressive metastatic astrocytoma with a median survival of 14 months and less than 5% of patients survive for 3 years [8] . This tumour is difficult to diagnose early as the tumour is usually asymptomatic or presents with symptoms which are difficult to associate with GBM, e.g. symptoms associated with a high intracranial pressure (headaches, nausea, vomiting and cognitive impairment) [9] . A major contribution to the poor survival rates is the insufficient transport of therapeutic molecules across the blood brain barrier (BBB) [10] . The current standard of care comprises surgical resection to the maximum possible extent, followed by concurrent radio-chemotherapy and adjuvant chemotherapy with temozolomide [2] . This treatment regimen became the standard improvement in the median survival as well as 27.2% two-year survival rates in glioblastoma patients, who had received post-surgical concomitant and adjuvant temozolomide (known as the Stupp regimen) compared to 10.9% two-year survival rates with post-surgical radiotherapy alone [11] . For recurrent glioblastoma on the other hand, there is currently no standard treatment regimen [12] , and thus patients frequently receive investigational agents in clinical trials [13] .
The Blood Brain Barrier (BBB)
The treatment of brain tumours (or more generally, central nervous system (CNS) tumours) is particularly challenging, mainly because of their intracranial location [14] . Intracranial protected by the intact blood brain barrier (BBB), which maintains the brain microenvironment by serving as a physical and metabolic barrier regulating the access of molecules to the brain [15] . The physical barrier is formed by the tight junctions between the adjacent endothelial cells (which prevent blood-borne substances from crossing into the brain parenchyma), a lack of capillary fenestrations, very low pinocytotic activity and the metabolic barrier is formed by degradative enzymes, specialised transport receptors and endothelial cell efflux pumps [15] .
Other Brain Tumour Treatment Barriers
Another barrier thought to restrict access of systemically administered therapeutic agents to tumour cells is the brain tumour-cell barrier (BTB, a barrier due to the efflux activity of tumour cells) [16] . Other challenges associated with effective brain tumour treatment are: dose limiting toxicity, mainly myelosuppression and tumour resistance to alkylating agents; the latter mediated mainly by the overexpression of O 6 -methylguanine-DNAmethyltransferase (MGMT), a ubiquitous protein encoded by the MGMT gene [14] .
Passive Targeting with Nanoparticles
Nanoparticles have been used to passively target drugs to intracranial tumours, on intravenous injection, in order to enable delivery of therapeutics across the BBB to the brain, as there is evidence that nanoparticles are able to preferentially accumulate drug at tumour sites, when compared to the administration of drugs in solution [17] . Generally nanoparticles may be engineered to: a) enable tissue or organ specific transport of their drug payload, or b) enable the delivery of hydrophobic and metabolically labile drugs [18, 19] . Thus, nanoparticles are an interesting platform to consider in drug development for brain tumour indications [19] .
Intravenously administered nanoparticles for delivery of therapeutic agents to brain tumours may theoretically exploit the enhanced permeability and retention (EPR) effect, whereby particles extravasate through a leaky tumour vasculature and achieve closer proximity to the tumour cells [20] . However for the EPR effect to be operational, the BBB must be compromised at the site of the intracranial tumour and while the breakdown of the BBB is diagnostic of a high grade glioma [21] most tumours are associated with an intact BBB [22] and direct evidence of nanoparticle accumulation within intracranial tumour cells is difficult to find. Early activity in this area focused on the delivery of P-gp efflux pump substrates to the brain in an attempt to circumvent the blood tumour-cell barrier. The P-gp substrate [23] , doxorubicin, when intravenously injected in poly(butylcyanoacrylate) nanoparticles, resulted in increased tumour tissue accumulation, in a mouse C6 glioma rat model, when compared to healthy tissue and an attendant improvement in tumouricidal activity was observed with these nanoparticles when compared to the drug in solution [24] . Additionally, the formulation was also found to be less cardiotoxic. This provides indirect evidence that nanoparticles are able to take advantage of a variation in the BBB at the tumour site.
As well as the cyanoacrylates, other polymers have also demonstrated the tumour tissue drug accumulation phenomenon on intravenous injection. Doxorubicin loaded on to poloxamer 188-coated poly-(lactic acid-co-glycolic acid) (PLGA) nanoparticles in a rat glioblastoma 101/8 model resulted in superior tumouricidal activity, through the intravenous route, when compared to the drug in solution [25] .
Nanomedicines may also consist of more than one therapeutic for the treatment of brain tumours. For example, chitosan surface modified PLGA nanoparticles loaded with carmustine along with O 6 -benzylguanine (which depletes MGMT, thus improving the therapeutic efficacy of carmustine). On intravenous injection, this nanoparticle formulation yielded superior survival outcomes in F98 glioma-bearing rats compared to the administration of the two drugs separately in solution or to the nanoparticle containing carmustine alone [26] .
Nanoparticles may also work by simply increasing plasma exposure, which in turn increases brain exposure, while minimising exposure to areas of potential toxicity [27] . We have shown that lomustine loaded on to GCPQ (N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan) nanoparticles resulted in increased plasma and brain exposure, reduced liver and bone exposure and ultimately increased tumouricidal activity
(survival and tumour size) in a U87MG intracranial tumour model, without increasing myelosuppression [27] .
Active Targeting with Nanoparticles
Active targeting involves the use of carriers bearing various surface ligands to achieve either transport across an intact BBB, or alternatively, cell uptake following extravasation across a leaky BBB [28] .
Various across BBB transporters have been exploited for transport across an intact BBB, such as the transferrin receptor [29] and the GLUT receptor [30] . Transferrin -cyclo-[Arg-Gly- [29] . This resulted in drug accumulation in the brain and a superior anti-glioma effect compared to the commercial formulation, Taxol [29] . Others have utilised the T7 peptide (HAIYPRH) to target the endothelial cell transferrin receptor and achieve across BBB transport [31] . T7
peptide modified core-shell nanoparticles (T7-LPC/siRNA) have been shown, on intravenous administration, to accumulate anti-epidermal growth factor receptor (anti-EGFR) siRNA in intracranial tumour tissue, down regulate EGFR and increase survival rates in a U87MG mouse tumour model, when compared to plain nanoparticles [31] . While the T7 peptide appears to achieve delivery across the BBB [31] , efforts to improve cell uptake, once extravasation has taken place, have involved the use of dual targeting strategies, in which transport across the BBB is combined with a ligand promoting tumour cell uptake [32] .
Intravenously administered dual targeted doxorubicin liposomes comprising the TAT peptide (AYGRKKRRQRRR) for cellular uptake and the T7 peptide for across BBB transport resulted in increased delivery of doxorubicin to the brain glioma tissue in a C6 glioma mouse model and reduced delivery to the heart, which is relevant for the cardiotoxic [33] drug doxorubicin [32] .
Utilisation of the GLUT receptor to cross the BBB has been achieved by using 2-deoxy-Dglucose modified poly(ethylene glycol)-co-poly(trimethylene carbonate) paclitaxel nanoparticles [30] . The 2-deoxy-D-glucose moiety was correlated with drug accumulation in the brain and these glucose-decorated nanoparticles produced superior survival in an RG2 mouse glioma model, when compared to plain nanoparticles and Taxol [30] . [34, 35] , however the efficacy of this nanoparticle approach in the clinic has not yet been reported. 
Theranostics
Imaging agents and drugs transported by a single nanoparticle is another area of innovation that has been applied to the treatment of experimental brain tumours and these are known as theranostics [17, 36] . [39] . Across BBB delivery and tumour cell uptake properties were achieved using ApoE as ApoE is taken up by the low-density lipoprotein receptor (LDLR) on brain endothelial cells and tumour cells, where in the latter case, the LDLR receptor is upregulated [39] . After intravenous administration to a U87 Green Fluorescent Protein (GFP) mouse model, the particles were found to accumulate within brain tumour tissue.
These image competent nanotherapeutics may prove interesting in the treatment of diffuse brain metastasis in multiple brain regions. 
Conclusions
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Brain metastases and primary CNS tumours
Brain metastases are the most frequently occurring neurologic complications of cancer in adults, with 9 -17% of all cancers resulting in brain metastasis and brain metastasis occurring in 8 -14 per 100,000 in the general population [1] . Primary brain tumours, on the other hand, are relatively rare, and comprise about 1.4% of cancers [2] . Brain metastases are associated with a median survival times of about 3 -25 months [3] , and a 5 year survival rate of 1.8% [4] . Treatment modalities employed for brain metastases include: surgical resection, whole brain radiation therapy, radiosurgery and chemotherapy [5] . The choice of treatment would usually be based on several considerations. These include: histopathology of the primary tumour, status of systemic disease, patient's performance status (general well being and lifestyle activity level), age of the patient, number and sites and precise location of the brain metastases (such as proximity to sites of vital brain function), co-existing morbidities, and symptoms [2, 5] .
Glioblastoma multiforme (WHO Classification astrocytoma Grade IV), a metastatic primary brain tumour, accounts for 12 -15% of all brain tumours [6] and is the most common primary brain tumour in adults [7] . Glioblastoma is an aggressive metastatic astrocytoma with a median survival of 14 months and less than 5% of patients survive for 3 years [8] . This tumour is difficult to diagnose early as the tumour is usually asymptomatic or presents with symptoms which are difficult to associate with GBM, e.g. symptoms associated with a high intracranial pressure (headaches, nausea, vomiting and cognitive impairment) [9] . A major contribution to the poor survival rates is the insufficient transport of therapeutic molecules across the blood brain barrier (BBB) [10] . The current standard of care comprises surgical improvement in the median survival as well as 27.2% two-year survival rates in glioblastoma patients, who had received post-surgical concomitant and adjuvant temozolomide (known as the Stupp regimen) compared to 10.9% two-year survival rates with post-surgical radiotherapy alone [11] . For recurrent glioblastoma on the other hand, there is currently no standard treatment regimen [12] , and thus patients frequently receive investigational agents in clinical trials [13] .
The Blood Brain Barrier (BBB)
The treatment of brain tumours (or more generally, central nervous system (CNS) tumours) is particularly challenging, mainly because of their intracranial location [14] . Intracranial tumours are effectively "shielded" from the effects of most systemically administered cytotoxic agents. The brain parenchyma and most (but not all) intracranial tumours are protected by the intact blood brain barrier (BBB), which maintains the brain microenvironment by serving as a physical and metabolic barrier regulating the access of molecules to the brain [15] . The physical barrier is formed by the tight junctions between the adjacent endothelial cells (which prevent blood-borne substances from crossing into the brain parenchyma), a lack of capillary fenestrations, very low pinocytotic activity and the metabolic barrier is formed by degradative enzymes, specialised transport receptors and endothelial cell efflux pumps [15] . 
Other Brain Tumour Treatment Barriers
Another barrier thought to restrict access of systemically administered therapeutic agents to tumour cells is the brain tumour-cell barrier (BTB, a barrier due to the efflux activity of tumour cells) [16] . Other challenges associated with effective brain tumour treatment are:
dose limiting toxicity, mainly myelosuppression and tumour resistance to alkylating agents; the latter mediated mainly by the overexpression of O 6 -methylguanine-DNAmethyltransferase (MGMT), a ubiquitous protein encoded by the MGMT gene [14] .
Passive Targeting with Nanoparticles
Intravenously administered nanoparticles for delivery of therapeutic agents to brain tumours may theoretically exploit the enhanced permeability and retention (EPR) effect, whereby particles extravasate through a leaky tumour vasculature and achieve closer proximity to the tumour cells [20] . However for the EPR effect to be operational, the BBB must be compromised at the site of the intracranial tumour and while the breakdown of the BBB is diagnostic of a high grade glioma [21] most tumours are associated with an intact BBB [22] and direct evidence of nanoparticle accumulation within intracranial tumour cells is difficult to find. Early activity in this area focused on the delivery of P-gp efflux pump substrates to the brain in an attempt to circumvent the blood tumour-cell barrier. The P-gp substrate [23] , doxorubicin, when intravenously injected in poly(butylcyanoacrylate) nanoparticles, resulted in increased tumour tissue accumulation, in a mouse C6 glioma rat model, when compared to healthy tissue and an attendant improvement in tumouricidal activity was observed with these nanoparticles when compared to the drug in solution [24] . Additionally, the formulation was Nanomedicine   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r R e v i e w O n l y 4 also found to be less cardiotoxic. This provides indirect evidence that nanoparticles are able to take advantage of a variation in the BBB at the tumour site.
Nanoparticles may also work by simply increasing plasma exposure, which in turn increases brain exposure, while minimising exposure to areas of potential toxicity [27] . We have 
Active Targeting with Nanoparticles
Various across BBB transporters have been exploited for transport across an intact BBB, such as the transferrin receptor [29] and the GLUT receptor [30] . Transferrin -cyclo-[Arg-Gly- [29] . This resulted in drug accumulation in the brain and a superior anti-glioma effect compared to the commercial formulation, Taxol [29] . Others have utilised the T7 peptide (HAIYPRH) to
target the endothelial cell transferrin receptor and achieve across BBB transport [31] . T7
Utilisation of the GLUT receptor to cross the BBB has been achieved by using 2-deoxy-Dglucose modified poly(ethylene glycol)-co-poly(trimethylene carbonate) paclitaxel nanoparticles [30] . The 2-deoxy-D-glucose moiety was correlated with drug accumulation in the brain and these glucose-decorated nanoparticles produced superior survival in an RG2 mouse glioma model, when compared to plain nanoparticles and Taxol [30] .
While there is good preclinical evidence showing the efficacy of nanoparticles in rodent models of intracranial tumours, clinical evidence on the use of nanoparticles is harder to locate. There are some reports of clinical trials in brain tumour patients with passively targeted nanoparticles (Table 1 ): e.g. NCT02340156, NCT02820454, NCT01266096, NCT03020017, NCT00734682 [34, 35] , however the efficacy of this nanoparticle approach in the clinic has not yet been reported. 
Theranostics
Imaging agents and drugs transported by a single nanoparticle is another area of innovation that has been applied to the treatment of experimental brain tumours and these are known as theranostics [17, 36] . An alternative method of labelling nanoparticles for imaging in a theranostic platform involves the use of porphyrin for near infrared imaging and as such 30 nm porphyrin-lipid apolipoprotein E3 (apoE3) lipid nanoparticles (pyE-LNs) with intrinsic imaging properties via the porphyrin lipid have been studied [39] . Across BBB delivery and tumour cell uptake properties were achieved using ApoE as ApoE is taken up by the low-density lipoprotein receptor (LDLR) on brain endothelial cells and tumour cells, where in the latter case, the LDLR receptor is upregulated [39] . After intravenous administration to a U87 Green Fluorescent Protein (GFP) mouse model, the particles were found to accumulate within brain tumour tissue.
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